Co-Diagnostics Total Assets Growth & History (CODX)
Co-Diagnostics's total assets was $24.7M for fiscal 2025.
View full Co-Diagnostics company overviewCo-Diagnostics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.7M | −$38.8M | −61.07% |
| 2024 | 2024-12-31 | $63.6M | −$31.8M | −33.32% |
| 2023 | 2023-12-31 | $95.3M | −$27.8M | −22.56% |
| 2022 | 2022-12-31 | $123.1M | −$36.9M | −23.09% |
| 2021 | 2021-12-31 | $160.0M | $88.8M | +124.65% |
| 2020 | 2020-12-31 | $71.2M | $69.0M | +3115.65% |
| 2019 | 2019-12-31 | $2.2M | $662,154 | +42.63% |
| 2018 | 2018-12-31 | $1.6M | −$3.1M | −66.69% |
| 2017 | 2017-12-31 | $4.7M | $3.4M | +259.80% |
| 2016 | 2016-12-31 | $1.3M | — | — |
Co-Diagnostics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.6M | −$29.9M | −64.29% |
| Q1 2026 | 2026-03-31 | $21.5M | −$33.6M | −61.02% |
| Q4 2025 | 2025-12-31 | $24.7M | −$38.8M | −61.07% |
| Q3 2025 | 2025-09-30 | $44.7M | −$27.6M | −38.19% |
| Q2 2025 | 2025-06-30 | $46.5M | −$34.2M | −42.42% |
| Q1 2025 | 2025-03-31 | $55.1M | −$31.5M | −36.37% |
| Q4 2024 | 2024-12-31 | $63.6M | −$31.8M | −33.32% |
| Q3 2024 | 2024-09-30 | $72.4M | −$36.3M | −33.40% |
| Q2 2024 | 2024-06-30 | $80.7M | −$32.1M | −28.46% |
| Q1 2024 | 2024-03-31 | $86.7M | −$30.3M | −25.92% |
| Q4 2023 | 2023-12-31 | $95.3M | −$27.8M | −22.56% |
| Q3 2023 | 2023-09-30 | $108.7M | −$39.2M | −26.49% |
| Q2 2023 | 2023-06-30 | $112.8M | −$48.0M | −29.87% |
| Q1 2023 | 2023-03-31 | $117.0M | −$54.2M | −31.64% |
| Q4 2022 | 2022-12-31 | $123.1M | −$36.9M | −23.09% |
| Q3 2022 | 2022-09-30 | $147.8M | $42.5M | +40.32% |
| Q2 2022 | 2022-06-30 | $160.8M | $68.1M | +73.34% |
| Q1 2022 | 2022-03-31 | $171.2M | $90.0M | +110.99% |
| Q4 2021 | 2021-12-31 | $160.0M | $88.8M | +124.65% |
| Q3 2021 | 2021-09-30 | $105.4M | $50.7M | +92.79% |
| Q2 2021 | 2021-06-30 | $92.8M | $54.0M | +139.20% |
| Q1 2021 | 2021-03-31 | $81.1M | $60.6M | +296.08% |
| Q4 2020 | 2020-12-31 | $71.2M | $69.0M | +3115.65% |
| Q3 2020 | 2020-09-30 | $54.7M | $50.8M | +1333.69% |
| Q2 2020 | 2020-06-30 | $38.8M | $33.5M | +629.45% |
| Q1 2020 | 2020-03-31 | $20.5M | $14.4M | +234.57% |
| Q4 2019 | 2019-12-31 | $2.2M | $662,154 | +42.63% |
| Q3 2019 | 2019-09-30 | $3.8M | $1.1M | +40.48% |
| Q2 2019 | 2019-06-30 | $5.3M | $3.3M | +170.02% |
| Q1 2019 | 2019-03-31 | $6.1M | $2.8M | +83.99% |
| Q4 2018 | 2018-12-31 | $1.6M | −$3.1M | −66.69% |
| Q3 2018 | 2018-09-30 | $2.7M | −$3.3M | −55.17% |
| Q2 2018 | 2018-06-30 | $2.0M | $1.5M | +321.20% |
| Q1 2018 | 2018-03-31 | $3.3M | — | — |
| Q4 2017 | 2017-12-31 | $4.7M | $3.4M | +259.80% |
| Q3 2017 | 2017-09-30 | $6.1M | — | — |
| Q2 2017 | 2017-06-30 | $467,580 | — | — |
| Q4 2016 | 2016-12-31 | $1.3M | — | — |
Co-Diagnostics total assets trends
Over the last five fiscal years, Co-Diagnostics's total assets decreased from $71.2M to $24.7M, a change of −$46.5M. The latest reported quarter, Q2 2026, shows $16.6M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Co-Diagnostics source filings ↗